Enanta Pharmaceuticals Inc. announced top-line results from the biotechnology company’s ARGON-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).
Akarna Therapeutics Ltd. announced that it has been acquired by Allergan plc. Allergan obtains rights to AKN-083, Akarna’s lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
2016 Annual Report: State Of The Bio Industry
Acute Myeloid Leukemia (AML), Analysts, Approvals, Biliary Atresia, Biopharma, Biotech, Biotech/Biopharma, Biotechnology, Checkpoint Inhibitors, Farnesoid X Receptor (FXR) Agonists, Forecasts, Immune System, Immune Systems, Immuno-oncology, Issue Archives, June 2016, Liver Disease, M&A, M&A, Nonalcoholic Steatohepatitis (NASH), PD-1/PD-L1 inhibitors, PD-L1 Inhibitor, Potential Blockbusters, Pricing, Primary Sclerosing Cholangitis (PSC), Special Reports, T-CellsThe outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
